Hebei Changshan Biochemical Pharmaceutical Co Ltd: A Surge in the Pharmaceutical Sector

On May 29, 2025, the A-share market witnessed a significant uptick, with the Shenzhen Stock Exchange seeing notable gains. The Shenzhen Composite Index and the ChiNext Index rose by over 1%, while the Hong Kong market also experienced a substantial rally, with the Hang Seng Index climbing over 1% and the Hang Seng Tech Index surging over 2%.

Market Dynamics and Key Players

The A-share market’s three major indices showed strong midday gains, with the Northern 50 Index rising by nearly 3%. By the close, the Shanghai Composite Index increased by 0.7% to 3363.45 points, the Shenzhen Composite Index rose by 1.24% to 10127.2 points, and the ChiNext Index climbed by 1.37% to 2012.55 points. The Northern 50 Index saw a significant rise of 2.73%. The total trading volume across the Shanghai, Shenzhen, and Northern markets reached 12136 billion yuan, marking an increase of nearly 1800 billion yuan from the previous day.

Over 4400 stocks turned red, with the semiconductor sector leading the charge. Companies like LeGrand Electronics and Guangli Micro surged by 20% to their daily highs. The innovative drug concept saw heightened activity, with stocks like Ruizi Pharmaceutical, YiFang Biotechnology, and ShuTaiShen reaching 20% daily highs. Changshan Pharmaceutical also saw a rise of over 15%, setting a new high.

Hebei Changshan Biochemical Pharmaceutical Co Ltd’s Performance

Hebei Changshan Biochemical Pharmaceutical Co Ltd, a healthcare company listed on the Shenzhen Stock Exchange, focuses on the research, development, production, and sales of heparin products. Its offerings include heparin sodium APIs, LMW heparin calcium injections, heparin sodium injections, sodium hyaluronate, hard capsules, and Yihaitang capsules—an anti-aging health product. The company also markets and sells reviparin sodium, hyaluronic acid, and heparinoid APIs.

On May 26, 2025, the company’s closing price was 31.7 CNY, with a 52-week high of 32.77 CNY and a low of 8.65 CNY on July 24, 2024. The market capitalization stood at 16,818,814,281 CNY.

Innovative Drug Sector and Global Presence

The innovative drug concept continued to gain momentum, with stocks like Ruizi Pharmaceutical, YiFang Biotechnology, and ShuTaiShen reaching 20% daily highs. Changshan Pharmaceutical also saw a significant rise of over 15%, setting a new high. This surge is part of a broader trend in the pharmaceutical sector, driven by advancements in innovative drug development and increased global demand.

Hebei Changshan Biochemical Pharmaceutical Co Ltd operates globally in approximately 30 countries and districts, showcasing its international presence and commitment to expanding its market reach.

Conclusion

The recent market rally highlights the growing investor interest in the pharmaceutical sector, particularly in innovative drug development. Companies like Hebei Changshan Biochemical Pharmaceutical Co Ltd are well-positioned to capitalize on this trend, given their focus on cutting-edge products and global market presence. As the sector continues to evolve, stakeholders will closely watch for further developments and opportunities.